The Food and Drug Administration approved Johnson & Johnson's Spravato last month for treatment-resistant depression. J&J on Tuesday said the first patients have been treated and up to 800 clinics are certified to administer the drug.
Up to 800 health centers have been approved to administer Johnson & Johnson's new ketamine-like depression drug, which was cleared for sale last month, and patients are already using it, the company said Tuesday.
For more on investing in health care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Scientists edge closer to understanding how ketamine can treat depressionThe research comes amid a 'psychedelic renaissance,' in which scientists have investigated whether psychoactive drugs such as MDMA and LSD could be used to treat mental illnesses such as depression, anxiety and PTSD.
Weiterlesen »
Scientists edge closer to understanding why ketamine can treat depressionThe research comes amid what is known as the psychedelic renaissance, which has seen scientists investigate whether psychoactive drugs such as MDMA and LSD could be used to treat mental illnesses like depression, anxiety and PTSD.
Weiterlesen »
Tiger starts strong, one back of early Masters co-leadersTiger Woods made a solid start in his pursuit of a fifth Masters title with a qu...
Weiterlesen »
More gains ahead for the market after strong start to 2019, history showsThe S&P 500 has followed up three straight months of gains to start a year with an average rise of 7.23% over the next nine months.
Weiterlesen »
Virginia drug company charged in billion-dollar opioid marketing fraud scheme aimed at addictsProsecutors allege that Indivior, which sells the drug known as suboxone film, used a telephone 'helpline' to connect opioid-addicted patients to doctors who were prescribing the drug 'in a careless and clinically unwarranted manner.'
Weiterlesen »
Republicans warn drug companies not to cooperate with investigationCongress is investigating how the pharmaceutical industry sets prices. Two far-right members are warning the companies about cooperating with the probe.
Weiterlesen »
Value investor Joel Greenblatt says he likes Booking Holdings, thinks Align is too expensiveJoel Greenblatt told CNBC that he likes online travel company Booking Holdings and remains short medical device maker Align Technology.
Weiterlesen »
Art Cashin: If trade war starts to look semipermanent, stocks will 'definitely sell off'Concerns about trade are weighing on the stock market — and it could get worse, says veteran trader Art Cashin.
Weiterlesen »
Trump says administration giving ‘strong considerations’ to releasing immigrant detainees in ‘sanctuary cities’House Speaker Nancy Pelosi blasted the White House following a Washington Post report that Trump officials sought to release migrants into the districts of Democratic foes.
Weiterlesen »